Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2022-01-04 Regulatory Filings
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC for registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is a registration statement for the company's common stock to be listed on Nasdaq. The document does not contain financial statements, earnings data, or management discussion. It is a regulatory filing related to securities registration, not an annual report, earnings release, or other financial report. The document length is 3338 characters, which is relatively short and focused on registration information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-01-04 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) filed pursuant to Rule 433, which is a type of marketing communication related to securities offerings. It announces the submission of a Marketing Authorization Application (MAA) for a pharmaceutical product and provides clinical trial data and forward-looking statements. There are no financial statements, earnings data, or regulatory filings typical of annual or quarterly reports. The document is not a report itself but a communication related to marketing and regulatory progress. Given the nature of the document as a prospectus-type announcement related to capital markets and securities offering, it fits best under Capital/Financing Update (CAP). The document length is 7496 characters, sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2022-01-04 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC by Amylyx Pharmaceuticals, Inc. The S-1 form is used for initial public offerings (IPOs) to register securities with the SEC. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, management discussion and analysis, executive compensation, and other disclosures typical of a registration statement for an IPO. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or a proxy statement. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-01-03 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel to the SEC Division of Corporation Finance responding to comment letters regarding a Draft Registration Statement on Form S-1 for Amylyx Pharmaceuticals, Inc. It references Amendment No. 2 to the Draft Registration Statement and discusses detailed responses to SEC staff comments on clinical trial disclosures and stockholder information. The document is not the registration statement itself but a correspondence addressing SEC comments on the registration filing. It is a regulatory communication related to the registration process, not a financial report, earnings release, or other report type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2021-12-16 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) by Amylyx Pharmaceuticals, Inc. The S-1 form is used for initial public offerings (IPOs) to register securities for sale to the public. The text includes detailed information about the offering, company overview, risk factors, management discussion, financial statements, and other disclosures typical of an IPO registration statement. It is not an annual report, earnings release, or any other type of financial or regulatory filing listed in the categories. The S-1 registration statement is a capital markets filing related to the company's initial public offering and fundraising activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-12-16 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. Given the lack of meaningful content, the appropriate classification is the fallback category, Regulatory Filings (RNS).
2021-12-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.